Search

Displaying results 2861 - 2870 of 7059 in total
  1. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    allowing for administration in a one-hour infusion twice-a-year following the starting dose. … [A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab

  2. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

    Synonyms: Botulinum Neurotoxin A immune FAB2 (equine), BOTULINUM NEUROTOXIN A IMMUNE FAB2, EQUINE
  3. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    WP-1122 is a prodrug of 2-deoxy-D-glucose (2-DG). It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

    Synonyms: 3,6-di-O-acetyl-2-deoxy-D-glucopyranose, an acetic acid diester of 2-deoxy-D-glucose
  4. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.

  5. Drug

    Sincalide

    go.drugbank.com/drugs/DB09142
    Approved

    Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. … When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract.

  6. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. … [A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA.

    Mixtures: IMIPENEM/CILASTATINA POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, ARZOMEBA PISA 500MG/500MG (IMIPENEM+CILASTATINA) POLVO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE
  7. Drug

    Afacifenacin

    go.drugbank.com/drugs/DB21385
    Experimental

    Afacifenacin has a monoisotopic molecular weight of 481.2 Da. … Afacifenacin is a small molecule drug. The usage of the INN stem '-fenacin' in the name indicates that Afacifenacin is a muscarinic receptor antagonist.

  8. Drug

    Fosifidancitinib

    go.drugbank.com/drugs/DB21462
    Experimental

    Fosifidancitinib has a monoisotopic molecular weight of 505.12 Da. … Fosifidancitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Fosifidancitinib is a Janus kinase inhibitor.

  9. Drug

    Gemnelatinib

    go.drugbank.com/drugs/DB21513
    Experimental

    Gemnelatinib has a monoisotopic molecular weight of 524.23 Da. … Gemnelatinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Gemnelatinib is a tyrosine kinase inhibitor.

  10. Drug

    Girocitinib

    go.drugbank.com/drugs/DB21692
    Experimental

    Girocitinib has a monoisotopic molecular weight of 326.14 Da. … Girocitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Girocitinib is a Janus kinase inhibitor.